Results 61 to 70 of about 6,304,439 (300)

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Tumor-specific MHC-II guides anthracycline exemption and immunotherapy benefit in breast cancer

Biomarker Research
Background Anthracycline-based chemotherapy, while foundational in breast cancer treatment, confers substantial cardiotoxicity. Identifying biomarkers to guide anthracycline exemption without compromising efficacy has remained an unresolved clinical ...
Zehao Wang, Yanhui Wang, Zhishuang Gao, Yue Zhou, Xiaoting Chen, Rui Xu, Yangsiyuan Zhao, Yi Zhang, Bingqiu Xiu, Jing Liu, Zhiming Shao, Shengmei Gu, Jingyan Xue, Jiong Wu   +13 more
doaj   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Moonshots and metastatic disease: the need for a multi-faceted approach when studying atypical responses

npj Breast Cancer, 2017
Clinical research generally focuses on results involving a statistical mean with little attention in trial design to patients who respond considerably better or worse than average.
Kristine De La Torre, Elly Cohen, Anne Loeser, Marc Hurlbert, on behalf of the Metastatic Breast Cancer Alliance   +4 more
doaj   +1 more source

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

New England Journal of Medicine, 2012
Background Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)–targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1. The
S. Verma, D. Miles, L. Gianni, I. Krop, M. Welslau, J. Baselga, M. Pegram, D. Oh, V. Diéras, E. Guardino, L. Fang, Michael W. Lu, S. Olsen, K. Blackwell   +13 more
semanticscholar   +1 more source

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.

Journal of Clinical Oncology, 2020
PURPOSE To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS A multidisciplinary international Expert Panel
K. Allison, M. Hammond, M. Dowsett, Shannon E McKernin, L. Carey, P. Fitzgibbons, D. Hayes, S. Lakhani, M. Chávez-MacGregor, J. Perlmutter, C. Perou, M. Regan, D. Rimm, W. Symmans, E. Torlakovic, E. Torlakovic, Leticia Varella, G. Viale, G. Viale, T. Weisberg, L. McShane, A. Wolff   +21 more
semanticscholar   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study

BMC Cancer
Aims This investigation aims to elucidate the treatment status of advanced HR+/HER2- breast cancer patients in Hunan Province of Central Southern China from November 2021 to December 2022.
Zhe-Yu Hu, Binliang Liu, Ning Xie, Xiaohong Yang, Liping Liu, Huawu Xiao, Jing Li, Hui Wu, Jianxiang Gao, Jun Lu, Xuming Hu, Min Cao, Zhengrong Shui, Can Tian, Quchang Ouyang   +14 more
doaj   +1 more source

Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer

New England Journal of Medicine, 2019
Background Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy have a worse prognosis than those who have no residual cancer.
G. von Minckwitz, Chiun-Sheng Huang, M. Mano, S. Loibl, E. Mamounas, M. Untch, N. Wolmark, P. Rastogi, A. Schneeweiss, A. Redondo, H. Fischer, W. Jacot, A. Conlin, C. Arce-Salinas, I. Wapnir, C. Jackisch, M. DiGiovanna, P. Fasching, J. Crown, P. Wülfing, Z. Shao, E. R. Caremoli, Haiyan Wu, L. Lam, D. Tesarowski, M. Smitt, Hannah Douthwaite, S. Singel, C. Geyer   +28 more
semanticscholar   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source